Listen
REMICADE (rectocolite hémorragique active) (infliximab)
Opinions on drugs -
Posted on
Aug 05 2021
Reason for request
Reevaluation
Key points
Favourable opinion for maintenance of reimbursement in the treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
Clinical Benefit
| Substantial |
The Committee considers that the clinical benefit of REMICADE (infliximab) remains substantial in ulcerative colitis. |
Clinical Added Value
| Comments without ASMR value |
The Committee considers that the data from this study is not of a nature to modify its assessment of the clinical benefit formulated in its previous opinion of 7 May 2014. |
Documents
English version
Contact Us
Évaluation des médicaments
